Phase 3 Meningococcal Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
Healthy VolunteersMeningococcal Infection
Sanofi1,602 enrolled2 locationsNCT07135986
Recruiting
Phase 3
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
InfectionsMeningococcal
NPO Petrovax240 enrolled17 locationsNCT06834100
Recruiting
Phase 2Phase 3
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Meningococcal Infections
EyeGene Inc.1,123 enrolled1 locationNCT07204457